INTRODUCTION
============

Holoprosencephaly (HPE) is the most common congenital forebrain defect in humans. It results from failed or incomplete forebrain cleavage between days 18 and 28 of gestation ([@b16-0060537]; [@b35-0060537]).

The clinical presentation of HPE is remarkably variable, and the severity of the defects observed is evenly distributed along the HPE spectrum. The etiology is very complex and heterogeneous, involving chromosomal anomalies, multiple malformation syndromes and environmental factors. Fourteen genes are known to be involved in non-syndromic human HPE (*SHH, ZIC2, SIX3, TGIF, DISP1, NODAL, GLI2, PTCH1, TDGF1, FOXH1, FGF8, GAS1, DLL1* and *CDON*), but they explain only 30% of HPE cases ([@b37-0060537]). All mutations are found in the heterozygous state in HPE patients, and most are loss-of-function mutations ([@b15-0060537]; [@b4-0060537]; [@b45-0060537]; [@b46-0060537]; [@b5-0060537]; [@b18-0060537]). The correlation between the HPE phenotype and genotype is poor, and both sporadic cases and pedigrees display the extensive HPE phenotype variability. This suggests that heterozygous mutations of HPE genes might be insufficient to produce severe anomalies, and that HPE is the consequence of a complex interplay of developmental, genetic and environmental factors. To date, given the relatively low percentage of cases for which causative mutations have been identified, additional studies are undoubtedly warranted.

From animal model studies, multifactorial inheritance disorder has been proposed to contribute to the phenotype heterogeneity of the disorder. For example, heterozygous mutation of several genes belonging to the same or different pathways could lead to phenotypic heterogeneity. Mouse models have provided evidence, by implicating either one or two different signaling pathways \[*Nodal*^+/−^;*Smad2*^+/−^ ([@b42-0060537]); *Cd*o^−/−^;*Boc*^−/−^ ([@b57-0060537]); and *Chrd*^−/−^;*Nodal*^+/−^ ([@b55-0060537])\]. The genetic background also plays an important role in determining the severity of the phenotype, suggesting the existence of modifier genes ([@b9-0060537]; [@b30-0060537]; [@b21-0060537]; [@b43-0060537]). Furthermore, observation of some HPE patients with two different genetic alterations are consistent with a multigenic process ([@b37-0060537]; Ming and Muenke, 2002). Thus, the diversity of combinations of mutations in HPE genes and/or modifier genes belonging to different pathways could contribute to the wide spectrum of HPE phenotypes.

HPE genes belong to various different signaling pathways regulating forebrain development, including the Hedgehog (HH), NODAL, BMP and FGF pathways. The role of these pathways during forebrain development has been extensively studied, especially the SHH and NODAL pathways, the two major pathways implicated in the pathogenesis of HPE ([@b46-0060537]). However, the interactions between these pathways, in terms of spatial and temporal regulation during the development of HPE, need to be clarified.

The NODAL signaling pathway has been implicated in cases of human HPE with or without congenital heart defects and/or left-right disturbances ([@b47-0060537]; [@b48-0060537]). NODAL is a transforming growth factor β (TGF-β)-related signaling molecule that is essential during the initiation of gastrulation. NODAL signals act in the formation of mesoderm and are required later for correct positioning of the anteroposterior axis, midline patterning and left-right specification ([@b27-0060537]; [@b58-0060537]; [@b10-0060537]; [@b33-0060537]; [@b47-0060537]; [@b48-0060537]). The NODAL signaling pathway has been extensively studied during cleavage and blastula stages in zebrafish; NODAL acts in a dose-dependent and time-dependent manner during the mid-to-late blastula stage to specify most mesodermal and endodermal cell types ([@b23-0060537]; [@b22-0060537]). The total absence of NODAL is embryonically lethal, whereas a hypomorphic allele of *Nodal* or chemical inactivation results in anterior patterning defects including cyclopia in mice, zebrafish and *Xenopus* ([@b33-0060537]; [@b54-0060537]; [@b23-0060537]; [@b34-0060537]). These defects are strictly dependent on the degree of NODAL inactivation and on the embryonic stage. Consistent with the importance of this pathway during development, inactivation at early stages leads to very severe phenotypes, and the critical time-window of requirement for NODAL activity during forebrain formation is difficult to define ([@b52-0060537]; [@b34-0060537]).

###### TRANSLATIONAL IMPACT

**Clinical issue**

Holoprosencephaly (HPE), a remarkably common human birth defect, is caused by a failure to form the midline of the forebrain and midface. Its clinical presentation is extremely variable, ranging from alobar HPE (where there is a complete failure to divide the forebrain) to microform (where there are mild craniofacial features but no forebrain defects). Various craniofacial defects (from none to cyclopia) and other extra-craniofacial defects are observed. HPE is probably caused by both environmental and genetic factors; with respect to the latter, heterozygous mutations in components or regulators of the Sonic Hedgehog (SHH) signaling pathway are often associated. The phenotypic heterorogeneity seen in carriers of SHH pathway mutations, ranging from no clinical manifestation to alobar HPE, implicates other modifier genes in forebrain development.

**Results**

In addition to SHH signaling, several other pathways regulate forebrain development, such as the NODAL pathway. Here, the authors established a chick embryo culture model to investigate the effects of chemical inhibition of SHH and NODAL pathways during forebrain development. They report that inhibition of either pathway caused HPE-like defects with phenotypic variability. Inhibition of both pathways using subthreshold inhibitor concentrations acted synergistically to promote severe HPE-like phenotypes. These findings support the view that genetic heterogeneity plays a key role in HPE etiology and contributes to the phenotypic variability.

**Implications and future directions**

Because HPE arises from a complex interplay of developmental, genetic and environmental factors, it is difficult to study the condition using genetic approaches in a mouse model. By comparison, it is simpler to use cultured chick embryos for testing the multi-genetic hypothesis of human HPE and for validating new candidate genes. The identification of new modifier genes by whole exome sequencing will aid in the understanding HPE etiology, and provide new direction to mechanistic studies in the chick and in other model organisms.

Disruption of SHH signaling is a common major event in the development of HPE. Mice lacking SHH function have a severe HPE-like phenotype involving the absence of ventral forebrain structures and cyclopia ([@b8-0060537]). Studies with model organisms demonstrate that SHH produced by the prechordal mesendoderm is required for initiating the development of the midline of the forebrain and the midface ([@b51-0060537]; [@b39-0060537]; [@b29-0060537]). Abnormal activity of the SHH signaling pathway at particular periods of embryonic development might account for the phenotypical spectrum of HPE ([@b12-0060537]). There is a progressive mechanism whereby SHH produced by one midline structure induces *Shh* expression in successive midline structures. Most human HPE genes either encode components of the SHH pathway, or directly or indirectly affect *Shh* expression in either the prechordal mesendoderm or the developing ventral forebrain ([@b26-0060537]; [@b36-0060537]; [@b16-0060537]; [@b20-0060537]).

SHH and NODAL signals interact and Hedgehog signaling acts downstream from NODAL activity to pattern the ventral telencephalon ([@b40-0060537]; [@b50-0060537]). Indeed, expression of *Shh* is severely reduced in mutants for the NODAL pathway, particularly in anterior regions ([@b53-0060537]; [@b23-0060537]). The mechanisms by which NODAL signaling regulates SHH activity in axial tissues have yet to be determined, but NODAL signals can cell-autonomously promote floorplate-specific expression of *Shh* ([@b40-0060537]). The interaction between SHH and NODAL pathways takes place during gastrulation as the floorplate is established. The description of heterozygous mutations of *SHH* and *TGIF* (which interact with TGF-β-activated Smad proteins) in the same HPE patient is further evidence for there being interaction between SHH and NODAL ([@b41-0060537]). However, it is not known whether the association of effects in each of these two pathways can cause HPE.

Here, we studied partial chemical inhibition of these two pathways during chick forebrain development. Our aim was to evaluate the interaction between NODAL and SHH pathways and to investigate the HPE multiple-genetic process in an animal model using a dose- and time-dependent approach. We demonstrate that phenotypic severity was dependent on the stage of treatment and on the concentration of the chemical inhibitors of the NODAL and SHH signaling pathways. Subthreshold concentrations of the two inhibitors in combination caused severe effects. These investigations show that the partial inhibition of two pathways can have a cumulative effect in determining an HPE-like phenotype and support a genetic heterogeneity hypothesis for HPE.

RESULTS
=======

Inactivation of the NODAL signaling pathway from the stage of gastrulation onset leads to severe forebrain defects
------------------------------------------------------------------------------------------------------------------

The chemical inhibitor SB-505124 was used to inactivate NODAL signaling ([@b23-0060537]). This compound has been used previously to dissect the complex pathway of the TGF-β superfamily and has been validated for inhibition of the activin receptor-like kinase (ALK)4/5/7-dependent activation ([@b14-0060537]).

To analyze the effect of SB-505124 on chick forebrain during its formation, we studied three molecular markers: *Pax6*, *Shh* and *Nkx2.1*. The *Pax6* homeobox gene is specifically expressed in developing optic vesicles, making it a good indicator of eye defects, from hypotelorism to cyclopia, one of the main features of the HPE spectrum ([@b28-0060537]). *Shh* and *Nkx2.1* are ventral markers of the developing forebrain ([@b13-0060537]): they are targets of NODAL signaling during forebrain development and are specifically downregulated in animal models of HPE ([@b40-0060537]; [@b50-0060537]).

We used *ex ovo* chick embryo cultures (so-called roller cultures) to test the effects of NODAL signaling inhibition during early brain formation ([@b17-0060537]). The NODAL signaling pathway was inactivated in whole embryos from the onset of gastrulation (between stage 4 and stage 6 in the chick) until the primary regionalization of the forebrain (stage 12). The NODAL pathway is required during early gastrulation ([@b52-0060537]), so a concentration and a stage of treatment allowing gastrulation to occur but causing a forebrain phenotype had to be determined.

Whole chick embryos (*n*=317) from stage 4 to stage 6 were exposed to one of a series of SB-505124 concentrations: 10, 25, 50 or 75 μM. At least five different experiments were run for each condition. Because we clearly observed a phenotypic heterogeneity, we individualized three distinct phenotypes on the basis of the morphology and gene expression (arbitrarily classified as categories 1, 2 and 3) ([Fig. 1A](#f1-0060537){ref-type="fig"}).

![**NODAL signal inhibition by SB-505124 treatment leads to severe forebrain defects; the dose-response relationship is nonlinear.** (A) Ventral views of chick embryo heads at stage 12. Control embryos (*n*=150) were treated with DMSO (Aa, Ae, Ai). Other embryos were treated with one of a series of SB-505124 concentrations (10-75 μM) between stage 4 and stage 6 (*n*=317). Resulting phenotypes were classified into three categories according to morphology and *in situ* hybridization for *Pax6* (*n*=111) (Aa-Ad), *Shh* (*n*=107) (Ae-Ah) and *Nkx2.1* (*n*=99) (Ai-Al). The order of increasing severity was: category 1, category 2 and category 3. Arrowheads show the downregulation *of Shh* (Ag) and *Nkx2-1* (Ak) expression in the ventral forebrain. (B) Distribution of the phenotypes of stage 4+ embryos treated with one of a series of SB-505124 concentrations: 10 μM (*n*=15), 25 μM (*n*=20), 50 μM (*n*=22) or 75 μM (*n*=26). (C) Distribution of the phenotypes of embryos treated with 50 μM SB-505124 starting at various stages: from stage 4 (*n*=40), stage 4+ (*n*=22), stage 5 (*n*=29) and stage 6 (*n*=16). OV, optic vesicles; T, telencephalon; T\*, non-fused telencephalon; Cat, category.](DMM010132F1){#f1-0060537}

At the onset of the gastrulation (Stage 4+), most embryos (70%) treated with 25 μM SB-505124 were similar to controls (DMSO-treated embryos) in terms of morphology and expression of *Pax6*, *Shh* and *Nkx2.1* ([Fig. 1A](#f1-0060537){ref-type="fig"}, category 1). However, 30% of the embryos displayed a mild phenotype, involving forebrain hypoplasia ([Fig. 1A](#f1-0060537){ref-type="fig"}, category 2). In these category 2 embryos, optic vesicles were formed, as shown by *in situ* hybridization for *Pax6*, but they were in a more ventral position than in controls. They were fused only in rare cases. Importantly, expression of both *Nkx2.1* and *Shh* was specifically downregulated in the rostral diencephalic ventral midline ([Fig. 1A](#f1-0060537){ref-type="fig"}, arrowheads) similar to that described in several HPE models ([@b1-0060537]; [@b25-0060537]), including hypomorph mutants for NODAL signaling ([@b33-0060537]; [@b54-0060537]). At SB-505124 concentrations of 50 μM or 75 μM administered from stage 4+ ([Fig 1B](#f1-0060537){ref-type="fig"}), forebrain defects were severe (category 3) and characterized by anterior truncation with non-fused neural folds ([Fig. 1Ad, T\*](#f1-0060537){ref-type="fig"}), no formation of optic vesicles and downregulation of the expression of *Shh* and *Nkx2.1* in the rostral midline ([Fig. 1Ah,Al](#f1-0060537){ref-type="fig"}). This category 3 phenotype was observed in 59% and 77% of the embryos treated with 50 μM and 75 μM, respectively, from stage 4+.

We tested the response of chick embryos to SB-505124 according to the stage of treatment. The category 3 phenotype was frequent among embryos treated with 50 μM from stage 4 (68%) or 4+ (59%) ([Fig 1C](#f1-0060537){ref-type="fig"}), but this severe phenotype was significantly less frequent when the treatment was started at stage 5 (10%). After stage 5, severe phenotypes were not observed: category 2 was more frequent for stage 5 (59%) and category 1 for stage 6 (63%).

In conclusion, category 3 (severe) phenotypes were mainly observed at a drug concentration over 25 μM initiated at stages 4 or 4+, just at the onset of gastrulation.

Cyclopamine causes progressive cyclopia in a dose-dependent manner
------------------------------------------------------------------

Cyclopamine is a well-characterized chemical inhibitor of the SHH signaling pathway ([@b11-0060537]; [@b28-0060537]): it inhibits the morphogenetic activity of the SHH pathway by binding to and preventing activation of the transmembrane protein, Smoothened (Smo) ([@b7-0060537]; [@b32-0060537]). First, as for SB-505124, we identified the stages and concentrations at which cyclopamine caused HPE-like defects.

Chick embryos were exposed to cyclopamine concentrations between 0.006 μM and 2.5 μM at stage 4+ ([Fig. 2](#f2-0060537){ref-type="fig"}). After 24 hours of culture, the embryos were individually scored for morphological abnormalities and *Pax6* expression. A phenotypic index was calculated and the phenotypes were classified into three categories, from normal embryo, category I to embryos with fused optic vesicles, category III.

![**Cyclopamine causes cyclopia in a dose-dependent manner.** (A) Ventral views of chick embryo heads at stage 12. Three phenotypes were distinguished morphologically. *Pax6* mRNA was used as a marker for optic vesicles (*n*=70). The order of increasing severity was: category I, category II and category III. (B) Distribution of the phenotypes observed for embryos treated at stage 4+ by one of a series of concentrations of cyclopamine: 0.006 μM (*n*=30), 0.025 μM (*n*=38), 0.5 μM (*n*=48) or 2.5 μM (*n*=33). OV, optic vesicles; OV\*, single optic vesicle; T, telencephalon; Cat, category. Brackets highlight the distance between optic vesicles.](DMM010132F2){#f2-0060537}

All embryos treated with 0.006 μM of cyclopamine at stage 4+, showed normal head development (category I). Normal head development was similarly observed in 85% of the embryos treated with 0.025 μM cyclopamine. The other 15% showed partial fusion of the optic evaginations ventrally, as confirmed by analysis of *Pax6* expression. This was defined as the category II phenotype ([Fig. 2A](#f2-0060537){ref-type="fig"}). At a higher cyclopamine concentration (0.5 μM), we observed a new phenotype (category III) characterized by optic vesicle fusion, from partial fusion to cyclopia, associated with an elongated forebrain (35%) ([Fig. 2A](#f2-0060537){ref-type="fig"}). At the highest concentration of cyclopamine tested (2.5 μM), 75% of the embryos displayed a category III phenotype ([Fig. 2B](#f2-0060537){ref-type="fig"}).

To determine when Shh-dependent forebrain patterning occurs, embryos were treated with 2.5 μM cyclopamine at various stages. Exposure at stage 5 or 6 resulted in a high proportion of cyclopic embryos (data not shown). However, following treatment with 2.5 μM cyclopamine starting at stage 7, none of the embryos developed cyclopia.

These experiments describe the relationship between cyclopia and both the stage of treatment and cyclopamine concentration. They confirms the involvement of SHH in the ventralization of the forebrain during early gastrulation (stages 5 and 6) ([@b44-0060537]). These experiments also identified a subthreshold concentration (0.006 μM) of cyclopamine that has no apparent morphological effect on either head development or fusion of the optic vesicles.

Combined partial inhibition of SHH and NODAL signals leads to cyclopic embryos
------------------------------------------------------------------------------

We studied the effects of combined treatment with the inhibitors of the NODAL and SHH signaling pathways, at subthreshold concentrations. SHH signal inactivation between stages 4 and 6 was required to obtain cyclops (see above). NODAL inactivation before stage 5 was required to cause a forebrain phenotype. Therefore, we used stage 4+ embryos for these experiments.

Stage 4+ chick embryos (total *n*=187) in roller cultures were exposed to 0.006 μM cyclopamine or 25 μM SB-505124 or both. *Pax6* expression was studied in these embryos.

We defined three new phenotypic categories (I\* to III\*) to score the degree of fusion of optic vesicles. These categories are similar to those defined for cyclopamine treatment, but include progressive forebrain hypoplasia ([Fig. 3A](#f3-0060537){ref-type="fig"}). Thus, category I\* was defined as embryos with non-fused expression of *Pax6* in the optic vesicles ([Fig. 3Aa](#f3-0060537){ref-type="fig"}), and included morphologically normal embryos and embryos with slightly ectopic optic vesicles. Category II\* ([Fig. 3Ab](#f3-0060537){ref-type="fig"}) embryos displayed a phenotype with ectopic optic vesicles (ventral position) with continuous expression of *Pax6*. Category III\* was a severely affected phenotype with partial or complete fusion of the optic vesicle (cyclopia) associated with marked forebrain hypoplasia ([Fig. 3Ac,Ad](#f3-0060537){ref-type="fig"}). We scored the severity of the phenotypes after the three treatments ([Fig. 3B](#f3-0060537){ref-type="fig"}).

![**Simultaneous partial inhibition of NODAL and SHH causes HPE-like anterior neural defects in chick embryo.** (A) Ventral views of chick embryo heads at stage 12. Embryos were treated with SB-505124 (25 μM) and cyclopamine (0.006 μM) at stage 4+ (*n*=187). Three phenotypes were distinguished using *Pax6 in situ* hybridization. The order of increasing severity was: category I\*, category II\* and category III\*. (B) Phenotype distributions among embryos treated with cyclopamine (*n*=52), SB-505124 (*n*=59) or both (*n*=76) at stage 4+. The asterisks show the significant cumulative effect of the double treatment leading to the HPE-like phenotype (\**P*=4×10^−4^). OV, optic vesicles; OV\*, single optic vesicle; T, telencephalon; Cat, category.](DMM010132F3){#f3-0060537}

The most severe phenotype, category III\*, was never observed following treatment with 0.006 μM cyclopamine alone, and only 6% of these embryos displayed a category II\* phenotype ([Fig. 3B](#f3-0060537){ref-type="fig"}). Following treatment with 25 μM SB-505124 alone, 7% of the embryos were category II\* and 5% category III\*. About 20% of the embryos subjected to the double treatment were category II\* and 14% category III\*. The proportions of categories II\* and III\* differed significantly between combined and single inactivation groups (*P*=4×10^−4^).

Therefore, combination of the two inhibitors at subthreshold concentrations caused more severe midline abnormalities than either inhibitor alone. These findings suggest that abnormal NODAL and SHH signals interact to produce various HPE-spectrum phenotypes. Similar double treatment started at stage 5 (*n*=49) or stage 6 (*n*=20) did not have a greater effect than single treatments (data not shown).

DISCUSSION
==========

The molecular basis for the variable expressivity and reduced penetrance of HPE has not yet been identified. However, the digenism described in animal models for HPE supports the existence of a heterogeneous and multigenic mechanism in some human cases, in which the penetrance and expressivity of heterozygous loss-of-function mutations can be modulated by one or more other mutations ([@b37-0060537]; [@b49-0060537]). Here, we report the development of an animal model in which various signaling pathways can be simultaneously and partially inhibited. We used this model to inactivate the NODAL and SHH pathways, both major pathways implicated in human HPE, during forebrain development.

In knockout models, the loss of NODAL signaling blocks gastrulation and is embryonically lethal ([@b33-0060537]). However, analysis of Nodal-insufficient embryos revealed that although the gastrulation takes place, eye field and forebrain fail to develop properly and a HPE-like phenotype develops ([@b33-0060537]; [@b54-0060537]; [@b3-0060537]; [@b55-0060537]). Here, we used the ALK4/5/7 receptor inhibitor, SB-505124, for partial inhibition of the NODAL pathway during chick development. It was previously shown that this drug added to developing zebrafish at various stages of development causes a spectrum of phenotypes, including cyclopia, that are phenocopies of NODAL component mutants ([@b23-0060537]). Even though multiple ligands can activate the ALK4/5/7 receptors, our phenotypes resemble those resulting from reductions in nodal-related gene function ([@b54-0060537]; [@b3-0060537]; [@b55-0060537]). This suggests that the other activin-like ligands are either not implicated during the stages we examined or act downstream of Nodal signals.

It has not yet been established when NODAL signals contribute to the anterior midline specification in chick embryos. In our experiments, embryos were treated in roller culture with various concentrations of SB-505124 at the onset of gastrulation. The severity of the resulting defects in forebrain development depended both on the concentration of the inhibitor and the stage at which treatment started. NODAL is essential for gastrulation through the regulation of several major genes; however, the difficulty was to find a window and concentration at which the inhibition was strong enough to induce an HPE-like phenotype (category 2) without causing a phenotype that was too severe (category 3). During our SB-505124 treatment, analysis of *Pax6* expression did not reveal any typical cyclopic phenotype, whereas *in situ* hybridization evidenced reduced, or loss of, *Shh* and *Nkx2.1* expression in the rostral midline region. Despite the lack of the typical HPE phenotype, this absence of expression of *Shh* and *Nkx2.1* at the anterior boundary of expression support the idea that these category 2 embryos display a HPE-like phenotype ([@b33-0060537]; [@b2-0060537]; [@b54-0060537]; [@b1-0060537]; [@b25-0060537]). The crucial stage for NODAL signaling in our model is before stage 5, which is consistent with the description of NODAL expression: *Nodal* is expressed in the middle three-quarters of the primitive streak, excluding Hensen\'s node, up to stage 5; *Nodal* expression then ceases in the midline ([@b31-0060537]).

Cyclopamine treatment caused, in a dose-dependent manner, fusion of the optic vesicles up to cyclopia, the most severe typical craniofacial defect in HPE. Interestingly, in HPE patients with altered SHH signaling, midline malformation ranges from hypotelorism to complete cyclopia ([@b39-0060537]). The features of our model are consistent with the demonstration by Cordero et al. of a relationship between the timing of Hedgehog disruption and the severity of the facial phenotype ([@b12-0060537]). Interestingly, embryos subjected to cyclopamine treatment starting as late as stage 7 developed a cyclopic phenotype. This is in agreement with the continuous expression of *Shh* throughout the node at stage 4 and subsequently in the prechordal mesendoderm at stage 7, the crucial structure for ventral forebrain patterning ([@b13-0060537]).

We investigated whether minor defects in NODAL and SHH pathways can synergize to produce HPE disorders. Our preliminary experiments indicated that stage 4+ embryos were suitable for these experiments for two reasons. First, SB-505124 had the largest effect on head development when administrated at stage 4 and 4+. Second, the stage 4+ is easy to distinguish, but also very transient, leading to less variability in the results. We used concentrations of inhibitors that in isolation did not cause any severe forebrain defect or severe optic vesicle fusion (25 μM SB-505124 and 0.006 μM cyclopamine). The proportion of embryos with ventralized optic vesicles (category II\*) and fusion (category III\*) was substantially higher following double treatment than single treatment. An optic vesicle phenotype was observed in 34% of double-treated embryos, and optic vesicle fusion up to cyclopia in 15%. This effect was not reproduced when embryos were treated slightly later, at stage 5. These experiments show that minor inhibition of both SHH and NODAL pathways can lead to abnormal development of the forebrain midline, whereas similar inhibition of one or other in isolation does not. The penetrance of the phenotypes obtained was incomplete and variable, which is a common feature of most HPE models described ([@b33-0060537]; [@b1-0060537]; [@b57-0060537]; [@b12-0060537]).

Cyclopamine and SB-505124 single treatments as a combination of both inhibitors generated phenotypic heterogeneity. This variability, from no morphological anterior deficit to severe anterior truncation, is greater with intermediate concentration of inhibitors (50 μM for SB-505124 and 0.5 μM for cyclopamine at stage 4+); it reflects the importance of the quantitative requirement of the level of NODAL and SHH signaling during forebrain development.

NODAL and SHH signaling are decisive in forebrain fate determination and the corresponding genes are expressed simultaneously in the primitive streak and the prechordal plate. The mechanism by which NODAL signaling regulates SHH activity during gastrulation has yet to be determined. However, several studies have indicated that the NODAL pathway regulates ventral forebrain patterning through SHH-independent mechanisms ([@b50-0060537]; [@b38-0060537]). SHH might have to reach a threshold concentration to ensure proper forebrain development ([@b56-0060537]). The dose- and stage-dependent relationship we observe here is consistent with a threshold effect: slightly reduced NODAL signaling might cause a small downregulation of SHH, which produces a HPE phenotype only when associated with another small decrease in SHH signaling.

Overall, we demonstrate that weak inhibition of two signaling pathways, one downstream of the other, can lead to an HPE-like phenotype. A similar interaction between NODAL and BMP has also been demonstrated in forebrain development ([@b55-0060537]). Therefore, several independent genetic events influencing different signaling pathways involved in forebrain development, acting at the same or different embryonic stages, can cause the HPE phenotype, most probably through regulation of the main HPE signaling pathway, SHH. This could be the basis for the phenotypic heterogeneity observed in families segregating mutations in SHH. This is coherent with the systematic decrease of *Shh* in animal models with partial inhibitions of various signaling pathways ([@b30-0060537]; [@b19-0060537]; [@b20-0060537]; [@b55-0060537]). These observations are consistent with a 'multisignaling pathways-hit' model. It is likely that as-yet unidentified polymorphisms contribute to the hypomorphic effects involved in HPE. Further work with whole exome sequencing would help confirm this theory.

MATERIALS AND METHODS
=====================

Roller-tube culture and chemical inhibition in chick
----------------------------------------------------

Fertile hens\' eggs were incubated in a humidified room at 38°C. The embryos were staged according to Hamburger and Hamilton ([@b24-0060537]). They were collected at stages 4, 4+, 5 and 6 and cultured as described elsewhere ([@b17-0060537]). Five embryos, folded and sealed along the longitudinal axis, were transferred to a 5-ml plastic bottle containing 500 μl of Liebovitz medium. The bottles were placed on a roller apparatus rotating at 30 revolutions/minute, inclined at an angle of about 10° in a 38°C incubator. Development was then allowed to proceed for 24 hours. The embryos were treated with the following compounds: cyclopamine (Sigma) from a stock solution of 1 mg/ml in 2-hydroxypropyl-β-cyclodextrin (HBC, Sigma); and SB-505124 (Sigma-Aldrich), from a stock solution of 24 mg/ml in DMSO. No toxicity was observed up to 100 μM for SB-505124 ([@b14-0060537]). Embryos were treated with cyclopamine, SB-505124 or both included in the culture medium continuously, starting from stage 4 to stage 6. Control embryos were treated with DMSO (*n*=352) or HBC (*n*=115). In our culture conditions, about 90% of the embryos were morphologically normal; the only visible abnormalities in the other 10% were localized failures of neural tube closure. However, the anatomical regionalization and gene expression of *Pax6, Nkx2.1* and *Shh* were in all cases apparently normal.

Whole-mount *in situ* hybridization
-----------------------------------

Antisense digoxigenin-labeled riboprobes were used for whole-mount *in situ* hybridization on chicken embryos as previously described ([@b6-0060537]). Plasmids carrying chick *Shh, Nkx2.1* and *Pax6* were used as templates to generate the antisense riboprobes.

Statistical analysis
--------------------

Variables are expressed as numbers and percentages. Fisher\'s exact tests were used for comparisons. We used a type I error of 0.05, by convention.
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